What was the primary endpoint in the EMPA-Reg outcome study?
Contribution To Literature: The EMPA-REG OUTCOME trial showed that empagliflozin is superior to placebo in improving glycemic control and reducing CV events including mortality in patients with DM2 and established CV disease.
What does EMPA-Reg stand for?
EMPA-REG RENAL. Efficacy and Safety of Empagliflozin in Patients With Type 2 diabetes and Renal Impairment.
When was EMPA-Reg published?
Published in 2015, the multicenter Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes trial (EMPA-REG OUTCOME) randomized 7,020 patients to daily empagliflozin 10 or 25 mg or placebo.
How much was the relative risk reduction of HHF in Empa-Reg?
9 Furthermore, in patients with T2D and established atherosclerotic cardiovascular disease (ASCVD), the EMPA-REG OUTCOME trial showed that, when added to standard of care, empagliflozin (compared with placebo) significantly reduced the risk of cardiovascular (CV) death by 38%, all-cause mortality by 32%, and HHF by 35% …
How much was the relative risk reduction of incident or worsening nephropathy in Empa Reg?
In the EMPA-REG OUTCOME study, the composite renal outcome was the rate of incident or worsening nephropathy defined as progression to macroalbuminuria, doubling of creatinine level, with eGFR of ≤45 ml/min/1.73 m2, the initiation of dialysis, or death from renal disease.
How does empagliflozin reduce cardiovascular mortality?
Thus, results of this study conclude that the key factor that reduces cardiovascular death with use of empagliflozin is its ability to change renal sodium and glucose handing and contributing to reduction in fluid burden, ventricular stress, sudden cardiac decompensation.
How much was the relative risk reduction of incident or worsening nephropathy in Empa-Reg?
Are the cardiovascular risk reductions seen with empagliflozin in the EMPA-Reg outcome trial explained by conventional cardiovascular risk factors?
Conclusions: Empagliflozin-associated changes in conventional CV risk factors in EMPA-REG OUTCOME appear to explain only a small proportion of the CV and all-cause death reductions observed.
Which SGLT2 inhibitor is best for CKD?
Dapagliflozin belongs to a group of medicines called ‘sodium glucose co-transporter-2 (SGLT2) inhibitors. It is the first SGLT2 inhibitor to be recommended through NICE’s technology appraisal process for CKD.
Why is empagliflozin kidney friendly?
Empagliflozin was well tolerated in CKD patients. Conclusions: In EMPEROR-Reduced, empagliflozin had a beneficial effect on the key efficacy outcomes and slowed the rate of kidney function decline in patients with and without CKD, and regardless of the severity of kidney impairment at baseline.
Why is Jardiance good for the heart?
“Results from the EMPEROR-Reduced trial show that, when given to adults with heart failure with reduced ejection fraction, empagliflozin reduces the number of heart failure hospitalizations while slowing the decline of kidney function. These results are highly statistically significant and clinically important.”
What is the half life of empagliflozin?
Excretion The total body clearance of empagliflozin is 10.6 L per hour and the expected half-life of empagliflozin is around 12.4 hours.
How does Empagliflozin reduce cardiovascular mortality?
Why are SGLT2 inhibitors contraindicated in renal failure?
Because SGLT2 inhibitors can cause contraction of blood volume, physicians are advised to consider factors that might increase the risk of acute kidney injury, including hypovolemia, chronic renal insufficiency, chronic heart failure, and concomitant medications (e.g. diuretics, angiotensin-converting enzyme inhibitors …
Does empagliflozin increase creatinine?
Additionally, the researchers said 1.8% of participants in the empagliflozin group had a doubling of serum creatinine accompanied by eGFR of 45 mL/min/1.73 m2 or less, initiation of renal-replacement therapy or death due to renal disease compared with 3.6% in the placebo group (HR = 0.48; 95% CI, 0.25-0.92).
What are side effects of empagliflozin?
Side Effects
- Bladder pain.
- bloody or cloudy urine.
- change in the color, amount, or odor of vaginal discharge.
- difficult, burning, or painful urination.
- frequent urge to urinate.
- itching, stinging, or redness of the vaginal area.
- pain during sexual intercourse.
Can Jardiance damage kidneys?
Kidney Problems. Sudden kidney injury has happened in people taking JARDIANCE. Talk to your doctor right away if you reduce the amount you eat or drink, or if you lose liquids; for example, from vomiting, diarrhea, or being in the sun too long.
Can you take empagliflozin with metformin?
Empagliflozin and metformin combination is used with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes. It is also used to lower the risk of death in patients with type 2 diabetes and heart or blood vessel disease.
What is the Empa-Reg outcome™ study?
The study is expected to report in 2015. EMPA-REG OUTCOME™ will determine the CV safety of empagliflozin in a cohort of patients with type 2 diabetes and high CV risk, with the potential to show cardioprotection.
What are the major points of the Empa-Reg study?
Major Points. Prior to this industry-sponsored trial, evidence demonstrating decreased significant renal events and mortality related to renal events in patients with type-2 diabetes was limited. The secondary outcome of the EMPA-REG study (EMPA-REG OUTCOMES) was a composite outcome of worsening nephropathy.
Are demographic and clinical characteristics balanced between placebo and empagliflozin groups?
At baseline, demographic and clinical characteristics were well balanced between the placebo group and the empagliflozin group (Table S2 in Section I in the Supplementary Appendix ).
What are the composite outcomes of empagliflozin therapy for angina?
The primary composite outcome was death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, as analyzed in the pooled empagliflozin group versus the placebo group. The key secondary composite outcome was the primary outcome plus hospitalization for unstable angina.